Boston Immune Technologies & Therapeutics
0 followers
‌
BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.
Industries
Headquarters
Employees
Links
Org chart
Russell LaMontagne
Collapse
David Brooks
Chief Medical Officer
Bruce Weaver
VP of Manufacturing
Elena Ende
Finance Director
Steve Andress
Director of Legal
Ken Olivier
Director of Preclinical Development
Mohammad Razvi
Director of Clinical Operations & Development
Similar companies
Viewpoint Molecular Targeting
1 follower
Amgen
187 followers
Thermo Fisher Scientific
149 followers
Genentech
145 followers
Gilead Sciences
123 followers
Regeneron
89 followers
Vertex Pharmaceuticals
50 followers
GRAIL
27 followers
Bio-Rad Laboratories
19 followers
Natera
12 followers
10X Genomics
11 followers
Discover companies